LAVA Therapeutics (LVTX) Competitors $0.96 +0.02 (+2.41%) Closing price 02/21/2025 03:49 PM EasternExtended Trading$0.97 +0.01 (+1.31%) As of 02/21/2025 06:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends LVTX vs. MGX, ELUT, ALTS, ORMP, MNOV, ACOG, SKYE, JMAC, TNYA, and CUEShould you be buying LAVA Therapeutics stock or one of its competitors? The main competitors of LAVA Therapeutics include Metagenomi (MGX), Elutia (ELUT), Janone (ALTS), Oramed Pharmaceuticals (ORMP), MediciNova (MNOV), Alpha Cognition (ACOG), Skye Bioscience (SKYE), Maxpro Capital Acquisition (JMAC), Tenaya Therapeutics (TNYA), and Cue Biopharma (CUE). These companies are all part of the "pharmaceutical products" industry. LAVA Therapeutics vs. Metagenomi Elutia Janone Oramed Pharmaceuticals MediciNova Alpha Cognition Skye Bioscience Maxpro Capital Acquisition Tenaya Therapeutics Cue Biopharma Metagenomi (NASDAQ:MGX) and LAVA Therapeutics (NASDAQ:LVTX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, risk, analyst recommendations, profitability, community ranking, valuation and earnings. Which has stronger valuation & earnings, MGX or LVTX? LAVA Therapeutics has lower revenue, but higher earnings than Metagenomi. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMetagenomi$44.76M1.97-$68.25MN/AN/ALAVA Therapeutics$6.77M3.72-$41.97M-$1.03-0.93 Does the media favor MGX or LVTX? In the previous week, Metagenomi had 4 more articles in the media than LAVA Therapeutics. MarketBeat recorded 4 mentions for Metagenomi and 0 mentions for LAVA Therapeutics. Metagenomi's average media sentiment score of 1.29 beat LAVA Therapeutics' score of 0.00 indicating that Metagenomi is being referred to more favorably in the media. Company Overall Sentiment Metagenomi Positive LAVA Therapeutics Neutral Does the MarketBeat Community favor MGX or LVTX? LAVA Therapeutics received 6 more outperform votes than Metagenomi when rated by MarketBeat users. However, 95.00% of users gave Metagenomi an outperform vote while only 69.44% of users gave LAVA Therapeutics an outperform vote. CompanyUnderperformOutperformMetagenomiOutperform Votes1995.00% Underperform Votes15.00%LAVA TherapeuticsOutperform Votes2569.44% Underperform Votes1130.56% Is MGX or LVTX more profitable? LAVA Therapeutics has a net margin of 0.00% compared to Metagenomi's net margin of -134.27%. Metagenomi's return on equity of -43.23% beat LAVA Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Metagenomi-134.27% -43.23% -18.86% LAVA Therapeutics N/A -62.22%-29.37% Do analysts rate MGX or LVTX? Metagenomi currently has a consensus price target of $16.67, suggesting a potential upside of 606.21%. LAVA Therapeutics has a consensus price target of $3.33, suggesting a potential upside of 248.13%. Given Metagenomi's stronger consensus rating and higher probable upside, equities research analysts plainly believe Metagenomi is more favorable than LAVA Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Metagenomi 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.86LAVA Therapeutics 0 Sell rating(s) 4 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.20 SummaryMetagenomi beats LAVA Therapeutics on 9 of the 13 factors compared between the two stocks. Get LAVA Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LVTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LVTX vs. The Competition Export to ExcelMetricLAVA TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$24.58M$7.06B$5.84B$9.15BDividend YieldN/A2.75%4.75%3.85%P/E Ratio-0.935.8226.1519.13Price / Sales3.72268.05435.3370.72Price / CashN/A65.6738.0134.83Price / Book0.496.717.644.62Net Income-$41.97M$138.55M$3.19B$245.94M7 Day Performance1.87%-2.63%-2.11%-2.62%1 Month Performance1.51%-2.33%-0.49%-2.15%1 Year Performance-53.06%-5.33%16.44%12.95% LAVA Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LVTXLAVA Therapeutics2.9368 of 5 stars$0.96+2.4%$3.33+248.1%-50.9%$24.58M$6.77M-0.9360Gap UpMGXMetagenomi1.8831 of 5 stars$2.61+6.5%$16.67+538.6%-79.1%$97.67M$44.76M0.00236News CoveragePositive NewsELUTElutia3.6048 of 5 stars$2.82-1.4%$10.00+254.6%-13.0%$97.46M$24.75M-1.08180News CoverageGap UpALTSJanoneN/A$6.90+10.6%N/AN/A$97.08M$39.61M0.00170News CoverageORMPOramed Pharmaceuticals1.4757 of 5 stars$2.40-2.0%N/A-33.0%$96.74M$1.34M21.8210Analyst DowngradeMNOVMediciNova2.4398 of 5 stars$1.97+5.3%$9.00+356.9%+35.6%$96.63M$1M-9.3810Earnings ReportAnalyst ForecastNews CoverageHigh Trading VolumeACOGAlpha CognitionN/A$6.03+5.4%N/AN/A$96.60MN/A-2.36N/AGap UpSKYESkye Bioscience1.2453 of 5 stars$3.16+3.3%$18.67+490.7%-52.1%$95.87MN/A0.0011News CoverageJMACMaxpro Capital AcquisitionN/A$7.11-0.8%N/A+1,067.4%$95.47MN/A0.002,021Gap DownTNYATenaya Therapeutics2.8824 of 5 stars$1.20+26.7%$17.33+1,344.4%-79.1%$95.07MN/A-0.83110Gap UpHigh Trading VolumeCUECue Biopharma4.1167 of 5 stars$1.49+4.9%$5.00+235.6%-36.5%$94.39M$5.49M-1.6660 Related Companies and Tools Related Companies Metagenomi Alternatives Elutia Alternatives Janone Alternatives Oramed Pharmaceuticals Alternatives MediciNova Alternatives Alpha Cognition Alternatives Skye Bioscience Alternatives Maxpro Capital Acquisition Alternatives Tenaya Therapeutics Alternatives Cue Biopharma Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:LVTX) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersAlert: DOGE goes live"It's Elon's world, and the rest of us live in it." Every investor in America is trying to figure out what ...Altimetry | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredNvidia’s Next Big Move Comes on Feb. 26Nvidia isn't the only company that benefits greatly from these earnings calls. That's because a handful of ...Weiss Ratings | SponsoredA strange twist 500 miles from WashingtonEnergy is life. And this year, it could also make national heroes out of President Trump and VP Vance. ...Porter & Company | SponsoredCollect $7k per month from Tesla’s SECRET dividendThere's a little-known secret about Tesla that even seasoned investors don't know. Despite not paying a tra...Investors Alley | SponsoredMajor AI announcement for 2025BIG NEWS: “Market Wizard” Larry Benedict Releases a Whole New Way to Trade AI StocksBrownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding LAVA Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share LAVA Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
